Alivus Life Sciences Limited (NSE: ALIVUS) announced its financial results for the second quarter and half-year ended September 30, 2026, showcasing a robust performance. Revenue from operations for Q2FY27 came at Rs. 6,820 Mn, marking a 16.0% year-over-year growth, driven by broad-based momentum in the non-GPL business which grew at 20.8% YoY. EBITDA for Q2FY27 stood at Rs. 2,851 Mn, a growth of 47.0% YoY with margins at 41.8%, up 520 bps QoQ & 880 bps YoY, driven by favourable product mix, new launches, and the benefits of operating leverage.

Strong Financial Performance

The company generated a strong free cash flow of Rs. 2,702 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 10,116 Mn as of September 30, 2026. Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, “Q2FY27 was another strong quarter for us, with revenue growing 16.0% YoY, supported by healthy demand across all key markets and robust contributions from recent launches. Non-GPL business momentum was maintained, while CDMO business saw a meaningful pick-up during the quarter. The improving business mix and greater operating efficiencies also translated into better underlying profitability. Looking ahead, our ongoing capacity expansion and healthy development pipeline give us confidence in sustaining this momentum and delivering consistent growth.”

Future Outlook

Tushar Mistry, CFO, Alivus Life Sciences Limited said, “We delivered a strong financial performance in Q2FY27, with healthy revenue growth, improved profitability and robust cash generation. Revenue grew 16.0% YoY, supported by a favourable product mix. Healthy operating performance translated into strong cash generation, with cash flow from operations of Rs. 270 crores during H1FY27. With cash and cash equivalents of Rs. 1,012 crores as of September 30, 2026, we have ample financial flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet. Going forward, we remain focused on sustaining profitable growth, maintaining financial discipline and creating long-term value.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alivus Life Sciences Limited

Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alivus gains 15.6% over three months and trades near its 52-week highs. The PEG stands at 4.11 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. The stock gives back 4.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.6% in three months on 6.9% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.

Sanofi India Limited’s board meeting commenced at 2:30 p.m. and concluded at 4:45 p.m. on October 29, 2026. The meeting focused on strategic initiatives and operational updates, underscoring the company’s commitment to innovation and growth in the pharmaceutical sector.

Strategic Initiatives

The board deliberated on several strategic initiatives aimed at expanding market reach and enhancing product portfolios. Notably, the meeting highlighted plans to strengthen partnerships in the cardiovascular and diabetes segments, which are pivotal to the company’s growth strategy.

Operational Updates

The meeting also provided updates on operational efficiencies and cost management. The board reviewed measures taken to improve gross margins and operational efficiencies, which have contributed to the company’s robust financial performance.

Future Outlook

As a result of these strategic discussions and operational reviews, Sanofi India Limited is poised to continue its momentum in the pharmaceutical industry, focusing on sustainable long-term value creation and market leadership.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sanofi India Limited

Sanofi India Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sanofi falls 13.8% over three months and has not found a floor yet. D/E of 0.00 and a 4.16% dividend yield give the balance sheet a decent cushion. The 4.16% dividend yield is about the only thing keeping income investors interested right now. The stock sits at 2% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at -12.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Sanofi India Limited.

Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare”) (NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostic company, today announced its results for the quarter ended September 30, 2026. Thyrocare reported consolidated revenue of INR 270.8 Cr in Q2FY27, up 25.1% year-on-year, driven primarily by a 26.7% increase in the Pathology segment.

Key Financial Highlights

Consolidated revenue registered a 25.1% year-on-year growth, driven primarily by a 26.7% increase in the Pathology segment. The exceptional item represents a one-time, non-cash impairment charge of Rs 45 Cr relating to NHL in consolidated books, recognised in connection with the definitive term sheet for the sale of the NHL business. This charge does not impact the Company’s operational performance.

Operational Performance

Thyrocare processed 61.6 million tests in Q2FY27, marking a strong 27.4% year-on-year growth and reinforcing its volume leadership position in the industry. The Pathology business maintained strong traction, with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year. Thyrocare’s commitment to quality continued to deliver Six Sigma-level performance, with complaints reduced to 2.9 per million (down 24% YoY) and an average turnaround time (ATAT) of 3.49 hours from sample receipt.

Future Outlook

Thyrocare continued its expansion into specialty diagnostics, marking the next phase of its growth journey. Having commenced with allergy and genomics, the Company is progressively expanding its specialty test portfolio, with a focus on building clinical trust through scientific rigour, uncompromising quality, and industry-leading turnaround times.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Thyrocare Technologies Limited

Thyrocare Technologies Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Thyrocare gains 42.8% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 36.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 87% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 16.7%, profits at 36.2%, and the PEG sits at 1.41 — below its growth rate. That combination is rare. Check Fundamentals of Thyrocare Technologies Limited.